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T cell-mediated cytotoxicity may play an important role 
in controlling infection by human immunodeficiency 
virus (HIV). In order to study the ability of rationally 
designed antigens to induce cytolytic T lymphocytes 
(CTLs) we replaced stretches of 30 to 50 amino acids at 
the p17-MA/p24-CA cleavage site, within the p24-CA 
moiety and within the p6-LI portion of the HIV type 1 
p55 gag precursor by the third variable domain (V3) of the 
external glycoprotein gpl20. This site is known to be a 
target for CTL attack in mice and humans. The chimeric 
antigens were recombined into highly attenuated vac- 
cinia viruses in order to investigate class I major 
histocompatibility complex (MHC)-restricted presen- 
tation of antigenic V3 peptides. Immunoprecipitation 
and Western blot analysis of the group-specific antigen 
(p55 g"g )/V3 chimeric proteins demonstrated significant 
differences in the accessibility of the V3 domain for a 
monoclonal antibody or polyclonal V3-specific antisera, 
depending on the position of the V3 loop within the 
p55 ~ag carder protein. Immunization of BALB/c mice 
with three variants of p55g"g/V3 recombinant vaccinia 
virus, however, esulted in a comparable priming of CD4- 
CD8 ÷ CTLs in vivo irrelevant of the position of the V3 
loop within p55 g"~. Local conformational changes, 
including the V3 domain within the p55g"g/V3 chimeras, 
did not demonstrate a significant effect on V3-specific 
lysis of the target cells when compared to the authentic 
gpl20 envelope protein. Class I MHC-restricted CTLs 
induced by a V3 consensus equence cross-reacted 
perfectly with the LAI strain-derived V3 loop sequence. 
These data indicate that the combination of selected 
epitopes (V3) with immunologically relevant complex 
carder proteins (p55g"0 can be accomplished without 
the loss of biological activity. 
Introduction 
Most successful vaccines closely mimic the pathogen or 
the natural infection, implying that natural infection 
leads to a long-lasting immunity. This is not so for 
human immunodeficiency virus (HIV) infection in 
humans. There is evidence that certain species of 
antibodies directed at defined epitopes within the HIV 
type 1 envelope proteins gpl20 and gp41 can enhance the 
ability of HIV to infect macrophages and monocytes 
(Robinson et al., 1989, 1990; Takeda et al., 1988) and 
contribute to severe immune dysfunctions by cross- 
reacting with modulators of the immune response such 
as class II major histocompatibility complex (MHC) 
molecules (Lasky et al., 1987; Young, 1988; Golding et 
al., 1988, 1989) and certain IgA and IgG subclasses 
(Maddon et al., 1986; Bjork, 1991). Most of these 
adverse ffects are associated with the envelope glyco- 
proteins gp41 and gpl20, which can directly contribute 
to the physical and functional e imination of helper T 
cells by binding to the CD4 receptor, thus labelling these 
cells for immune attack (Weinhold et al., 1989; Siliciano 
et al., 1988). 
With respect to future vaccine development, rationally 
designed antigens hould be as complex as possible. For 
safety reasons, however, epitopes known to be associated 
with negative side-effects should be xcluded and only 
immunologically defined epitopes, involved in eliciting 
protective immune responses, hould be considered for a 
candidate vaccine. To allow favourable presentation of 
these epitopes to the immune system we developed a
particulate, non-infectious and autologous carrier system 
based on the HIV-1 p55 group-specific antigen (p55gag; 
Wagner et al., 1991). By introducing foreign sequences 
into the native p55 gag protein, relevant epitopes can be 
presented by these virus-like particles (R. Wagner et al., 
unpublished). In addition to their crucial role during the 
budding process (G6ttlinger et al., 1989; Wagner et al., 
1992a: von Poblotzki et al., 1993) the HIV core proteins 
are able to induce inhibitory antibodies (Papsidero et al., 
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1989; Wolf et al., 1990) as well as cytolytic T lymphocytes 
(CTLs) (Nixon et al., 1988; Phillips et al., 1991). This 
suggests that p55 ga° is an appropriate, immunologically 
relevant carrier component. 
Epitopes to be inserted into this carrier protein should 
induce both neutralizing antibodies and an effective 
cellular immune response. This has been demonstrated 
for the third variable domain (V3) of HIV-1 gpl20 
(Rusche et al., 1988; Palker et al., 1988; Goudsmit et al., 
1988; Clerici et al., 1991). The induction of CTLs by a 
vaccine is of particular interest because of observations 
by several groups (Walker et al., 1987, 1989; Tsubota et 
al., 1989) that CD8 + CTLs could prevent outgrowth of 
HIV in vitro. If CTLs do the same in vivo (as suggested 
by D. Mosier at the international conference on AIDS), 
stimulation of this part of the immune response might 
prove very helpful in controlling disease. The ability of 
the V3 domain to generate CTLs, not only in humans but 
in BALB/c mice (Takahashi et al., 1988, 1990a, b, 1992; 
Hart et al., 1991), allows a rapid evaluation of chimeric 
antigens in a convenient animal model, and therefore 
suggests the V3 domain as a candidate epitope for 
insertion into the p55 gag carrier protein. 
One critical aspect in the induction of class I-restricted 
CD8 + CTLs by chimeric antigens is whether altered 
flanking sequences or changes in the local conformation 
at an antigenic site might co-determine processing and 
presentation of a translocated epitope. In order to 
address this question, three regions within the p55 gag 
precursor, the MA/CA cleavage site and the regions 
within the p24-CA domain product and the p6 portion of 
p55 g"g, were selected for their predicted logarithmic 
surface probabilities (Modrow et al., 1987) and replaced 
by a consensus sequence of the V3 domain (V3c). This 
epitope, previously designed to overcome the isolate 
specificity of antibodies directed towards the V3 domain, 
was shown to mediate killing of target cells by CD4- 
CD8 + CTLs induced in mice by a gpl20 (HIV strain 
LAI; gpl20~A~) recombinant vaccinia virus (VV) 
(Wagner et al., 1992b). Immunization of BALB/c mice 
with recombinant VVs expressing different p55g"g/V3c 
chimeric antigens should provide more information 
about the induction of CTLs by such artificial antigens. 
Methods 
Mice. BALB/c mice (H-2 a haplotype, Jackson Laboratories) were 
bred under specific pathogen-free conditions. 
Cells. CV-1 cells and 143B cells, grown in DMEM plus 10% fetal 
calf serum (FCS) (Gibco) were used to establish recombinant VVs. 
P815 cells, a continuously growing mastocytoma cell line (in RPMI 
with 10% FCS; Gibco), was used for the in vitro stimulation of 
splenocytes and as target cells in a 3 h cytolytic assay. 
Monoclonal antibodies. The monoclonal antibodies (MAbs) anti- 
Lyt2 (3.155; rat IgM) (Sarmiento et al., 1980) and anti-L3T4 
(RL172.4; rat IgM) (Ceredig et al., 1985) were used to characterize the 
surface phenotype of the effector cells. The V3-specific murine MAb, 
Nea 9301 (Du Pont), recognizes a central motif of the V3 loop region 
(RIQRGPGRAFVTIGKI), and the p24-CA-specific MAb used 
(16/4/2) was previously mapped to amino acids 307 to 336 within the 
capsid moiety of the p55 g"g precursor (Wolf et al., 1990). 
Selection of deleted epitopes. The three regions within the p55 g"g 
precursor, located at the MA/CA cleavage site, within the p24-CA 
domain product and within the p6-LI portion of p55 gag, were selected 
for their predicted antigenic indices and their logarithmic surface 
probabilities using computer-assisted secondary structure analysis of 
the HIV-1 group-specific antigen (UWGCG software). 
Construction of chimeric antigens. A new pUC8 derivative, plin8, has 
been constructed (Wagner et al., 1992a) and was treated as follows. 
The pUC8 multiple cloning site was replaced by a synthetic linker 
sequence containing all restriction sites (BamHI, HindlII, XhoI, SacI, 
PstI, SpeI and Sail) necessary for the construction of the described 
plasmids (Fig. 1). In order to delete the p17-MA/p24-CA cleavage site, 
including flanking amino acids 99 to 154, a 300 bp BamHI/HindlII 
fragment encoding the terminal part of p55 was cloned into the 
BamHI/HindlII site of plin8 (plin8p55BH). The 1283 bp NsiI/SalI 
fragment encoding the C-terminal part of p55 g"g was inserted into the 
PstI/SalI site of plin8p55BH to form plin8p55A1. A stretch of 30 amino 
acids (311 to 341) located within the p24-CA moiety was deleted by 
subcloning the complete 1752 bp BamHI/Sail fragment of pUC8p55 
into the BarnHI/Sall sites of plin8 (plin8p55) and replacing a 90 bp 
PstI/SpeI fragment by a 27bp XhoI/SacI linker fragment 
(TGCAGCTCGAGAATTCGAGCTCACTAG) (plin8p55A2). For 
the construction of deletion mutant p55A3 (lacking amino acids 483 to 
471 within p6), the original 3' part of the p55 gag coding sequence was 
replaced by a PCR fragment, amplified using a 64 bp 5' primer 
(CGACTCGGATCCAAGATCTCTCTCGAGAATTCGAGCTCG 
AAGAGAGATTCAGGTCTGGGGTAGA) containing four 5' re- 
striction sites (BgilI, XhoI, EcoRI, SacI) and a 21 bp 3' primer 
(TTCCAATTATGTCGACAGGTG) containing a 3' Sail site. The 
amplified BgilI/SalI fragment was inserted into the corresponding 
vector fragment of plin8p55 (plin8p55A3). The V3c sequence was then 
inserted into the XhoI/SacI sites of the above described p55 deletion 
constructs o create the p55gag/V3c- 1,-2, and -3 chimeric genes (Fig. 1). 
All subcloned V3 sequences including the flanking regions were verified 
by dsDNA sequencing. 
p55 gag precursor 
[ D17 (MA) H 1:)24 (CA) Ilpzmm I I~c~ I 
99 154 NN 17g71 495 p55gag/v3-1 
I 21~241 520 p55gag/v3-2 
] ~ '~ 515 p55gag/v3-3 
509 p5.°  
QCTRPNNNTRLRIRIGPGRAFVTIGKIGNMRQAHCN 
Fig. l. Schematic drawing of three different p55V3c constructs. The 
location of the V3c sequence relative to the p55 g"g precursor ismarked 
with the amino acid positions of the deleted gag sequences. The total 
number of amino acids of the resulting polypeptides is indicated. The 
designation ofthe resulting chimeric VVs is given at the right side of the 
figure. The V3 domain that replaced each of the gag sequences i
indicated below the constructs and the 12-mer within the 36-mer 
consensus peptide, an optimal CTL antigenic site, is underlined. 
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Recombinant vaccinia viruses. Recombinant VVs were established 
according to standard procedures (Mackett et al., 1984) after 
subcloning of the BamHI/SalI fragments into the pAvB VV transfer 
vector (von Brunn et al., 1991). The HIV-1 type IIIB gpl20-expressing 
vaccinia virus, vSC-25, kindly provided by Bernard Moss, has been 
described by Chakrabarti et al. (1986) and was used to infect the P815 
target cells. For the preparation of high titre virus stocks, CV-1 cells 
were grown to confluence. At 5 days after infection (m.o.i. of 1) the 
cells were harvested, resuspended in a small volume of PBS and 
sonicated three times for 10 s each at 150 W. The cell debris was 
discarded and the supernatant containing the enriched virus prep- 
aration was centrifuged over a 37'5 % sucrose cushion using a Kontron 
TFT41.14 rotor (36000 r.p.m, for 20 min at 4 °C). The pelleted virus 
was resuspended in a small volume of PBS and was centrifuged and 
resuspended once more as above. 
Detection and quantification of chimeric proteins. Expression of the 
chimeric proteins in cells infected with the recombinant VVs was tested 
by Western blot and immunoprecipitation analysis as previously 
described (Sambrook et al., 1989). Renaturation of the chimeric 
proteins following electrotransfer onto a nitrocellulose membrane was 
achieved by incubation of the Western blots in decreasing urea and 
DTT concentrations, diluted in PBS starting at 250 mM-DTT and 6 M- 
urea at 37 °C. Yields of the chimeric proteins were determined from 
crude cell lysates, after sonification of the infected cells, using a 
commercial ntigen capture assay (Abbott). 
Synthetic peptides and oligonueleotides. Peptides were synthesized in 
a 9050 peptide synthesizer (Milligen) using Fmoc-protected amino 
acids and were purified by reverse phase HPLC as described previously 
(Modrow et al., 1989). Oligonucleotides were synthesized in a Milligen 
DNA synthesizer. 
CTL generation. BALB/c mice were immunized intravenously with 
108p.f.u. recombinant VV. After 8 weeks, immune spleen cells 
(5x 106/ml in 24-well culture plates in complete T cell medium, 
comprising a 1:1 mixture of RPMI 1640 and EHAA medium 
containing 10% FCS, 2mM-g-glutamine, 100 units/ml penicillin, 
100 gl/ml streptomycin and 5 gM-2-mercaptoethanol) were restimu- 
lated in vitro for 6 days with 2.5 x 106 P815 cells/ml which had been 
infected with recombinant VV (for 1 h at 37 °C, 1 p.f.u./cell). After 
incubation with the virus, target cells were washed three times with PBS 
before addition to the spleen cells. This procedure was described 
previously and allows the stimulation of CTL over a limited period 
without resulting in a detectable ysis of the effector cells (Takahashi et 
al., 1988, 1989; Buseyne et al., 1993). Alternatively, spleen cells were 
stimulated in vitro with peptide-pulsed syngenic ells (2.5 x 105 cells/ml 
were incubated with the peptides, V3c-16, V3zA ~ -16 ornef-16, at 1 gM 
for 4 h, washed three times in PBS and then added to the splenocytes; 
Takahashi et al., 1992) in 10% rat concanavalin A supernatant- 
containing medium (rat T cell monoclone; Collaborative Research; 
Takahashi et al., 1988). 
CTL assay. Cytolytic activity of stimulated splenocytes was measured 
in a 3 h SlCr-release assay as described previously by Takahashi et al. 
(1988). For testing the peptide specificity of the CTLs, P815 target cells 
(1 x 106/ml) were incubated for 4 h at 37 °C with the appropriate 
peptides (1 gN) and labelled for 1 h with 100 laCi/ml Na25aCrO4 
(Amersham). All peptides used were shown to be non-toxic for the 
labelled target cells at concentrations up to 100 gM. Before use, target 
cells were carefully washed at least hree times in RPMI 1640 containing 
2 % FCS, to remove free peptide and 5aCr. 
Alternatively, target cells were infected for 1 h with the described 
recombinant VVs (10 p.f.u./cell, 37 °C) and were then washed with 
RPMI containing 1640 2% FCS, to remove free virus. The infected 
cells were then incubated overnight o allow the expression of the 
foreign genes from the VV 7.5K early/late promoter and were labelled 
for 1 h in the presence of 5aCr (100 gCi/ml) as described above. This 
procedure does not result in virus-mediated lysis of the target cells or 
even the generation of free virus within the test interval. 
Before use, the infected target cells were again washed at least hree 
times in RPMI 1640/2 % FCS to remove free 51Cr and were distributed 
at a concentration of 5 x 103 cells/well in 0.1 ml of medium in round- 
bottom 96-well plates. Various concentrations of the effector cells in 
0.1ml (in triplicate) were added (50:1 to 1:1). The plates were 
incubated at 37°C in 5% CO 2 for 3h and the cells were then 
centrifuged at 150 g for 5 min. Supernatants were collected and 51Cr 
c.p.m, was measured in a gamma counter. The percentage specific 51Cr 
release achieved for the indicated effector to target (E:T) ratios was 
calculated as 100 x [experimental release-spontaneous release)/ 
(maximum release-spontaneous release)]. Maximum release was 
determined from supernatants of cells that were lysed by the addition 
of 5 % Triton X-100. Spontaneous release was determined from target 
cells prepared as described above and incubated without added effector 
cells. Spontaneous release was below 10 % in all experiments. S.E.M.S of 
triplicate cultures were always less than 4 % of the mean. 
Results 
For  the appl icat ion o f  artif icial ly designed chimer ic  
prote ins  to immunizat ion  against  H IV  it is impor tant  to 
know to what  extent f lanking sequences or  local  
conformat iona l  changes at an ant igenic  site might  
contr ibute  to ant igen process ing and consecut ive  class I 
MHC- res t r i c ted  recogni t ion  o f  the ant igenic pept ide at 
the cell surface. 
To  address this quest ion  in H IV  infect ions three 
di f ferent p55gag/V3 ch imer ic  genes were establ ished at 
the DNA level. Three  regions with in  the p55 g~g precursor ,  
located at the p17-MA/p24-CA c leavage site (amino 
acids 99 to 154), wi th in  the p24-CA domain  product  
(amino acids 211 to 241) and wi th in  the p6-L I  por t ion  o f  
p55 gag (amino acids 436 to 471), were rep laced by the 
cod ing sequence o f  the V3 domain  and recombined  into 
VV strain T ien Tan  (v-TT).  The  recombinant  viruses 
were v-p55gag/V3c - 1, -2 and -3, depend ing  on the locat ion 
o f  the V3 domain  wi th in  the p55 gag precursor  (Fig. 1). 
Cor rect  express ion o f  the ch imer ic  prote ins  in P815 
mastocytoma cells was detected by a MAb (16 /4 /2 )  
which  specif ically recognizes amino  acids 307 to 336 
with in  the p24-CA por t ion  o f  p55 g~g (Wol f  et al., 1990), 
demonst ra t ing  that  the overal l  amount  o f  prote in  was 
comparab le  in all cell lysates cons idered (Fig. 2a). Us ing  
a commerc ia l  ant igen capture  assay, we calculated the 
amount  o f  recombinant  ant igen to be 1.0 to 1'2 ng/106 
infected cells. Shifts in the e lect rophoret ic  mobi l i ty  o f  the 
ch imer ic  po lypept ides  in re lat ion to p55 g~g chiefly 
corre lated with the number  o f  deleted amino  acids. The 
ant igenic i ty  o f  the inserted V3c domain  was proved  by a 
commerc ia l  gp 120LA~-specific mur ine  MAb recogniz ing a
15-mer V3 pept ide (R IQRGPGRAFVT IGK) .  Detect ion  
o f  the p55g~g/V3c ch imer ic  prote ins  wi th this LA I  isolate- 
specific MAb conf i rmed the cross-react ive propert ies  o f  
the inserted V3c sequence (Fig. 2b). The  dif ferent 
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Fig. 2. Analysis of p55V3 chimeric proteins, produced in P815 cells infected with various recombinant vaccinia viruses, by SDS~PAGE 
followed by immunoblotting, p55V3 chimeric proteins were detected by a MAb to p24 (a), by a gpl20-V3 loop-specific MAb (b) and 
by two different V3-specific polyclonal antisera raised in rabbits (c, d). (e, f )  Immunoprecipitation a alysis of lysates of P815 cells after 
infection with VVs. p55V3 chimeric proteins were precipitated (e) by the V3 loop-specific MAb and ( f )  by one of the V3-specific 
polyclonal rabbit antisera. Lane 1, wild-type vaccinia virus; lane 2, v-p55V3c-1 ; lane 3, v-p55V3c-2; lane 4, v-p55V3c-3 ; lane 5, v-p55. 
Shifts in the electrophoretic mobility chiefly correlate with the predicted M r of the recombinant proteins, indicated on the right. 
Specifically detected chimeric proteins are labelled by arrows. Positions of the M r markers are given on the left. 
p55°"~/V3c himeric proteins were also recognized by 
polyclonal antisera raised in rabbits towards the V3c 
peptide coupled to ovalbumin (serum A) or the free V3c 
36-mer loop peptide (V3c-36; serum B) (Fig. 2c, d). 
These antisera had previously been shown to contain 
conformation-dependent, in addition to sequence-speci- 
fic, antibodies (Wagner et al., 1992b). According to the 
position within p55 g"g recognition of the V3c domain by 
the V3LAI-specific MAb, as well as by the V3c-specific 
antisera, reproducibly differed among the cell lysates 
considered (Fig. 2b to d). The antigenicity of the V3c 
domain, which was very weak within p55gag/v3-1, could 
be clearly improved after insertion into more carboxy 
terminal portions of the p55 gag carrier protein, as 
demonstrated for p55gag/v3-2 or p55gag/v3-3. The 
protein o fM r 66K recognized inFig. 3 (c) is due to a cross- 
reaction of serum A with albumin. Major changes in the 
antigenicity might correlate with varying accessibility of 
the inserted V3c domain for V3-specific antibodies. To 
confirm this observation under altered, native conditions, 
we performed an immunoprecipitation analysis of lysates 
of P815 cells after infection with recombinant VVs using 
the V3LAi-specific MAb and a polyclonal V3-specific 
antiserum (serum B). The results (depicted in Fig. 2e and 
f )  show that the position of the V3c domain within the 
p55 g"g precursor clearly determines the accessibility of 
the V3 epitope for specific antibodies. Neither the V3Lz 
specific MAb nor the V3c-specific polyclonal antiserum 
precipitated the p55gag/v3 - 1 chimeric antigen, indicating 
that the V3c domain in this chimera is not accessible to 
V3-specific antibodies. Confirming the Western blot 
data, the antigenicity improved following insertion f the 
V3c domain into positions -2  and -3  (Fig. 2e and f). 
In order to investigate the influence of flanking 
sequences and changes in local conformations on the 
priming of V3c-specific CTLs, BALB/c mice were 
stimulated in vivo by recombinant VVs (v-p55V3-1, -2, 
-3; 108 p.f.u./mouse), described above. Syngenic p815 
target cells were used for a 7-day-long in vitro restimu- 
lation oftheisolated splenocytes (2 months post-infection) 
and as targets in a 3 h cytolytic assay. Previous experi- 
ments clearly demonstrated that V3-specific killing of 
target cells strictly correlates with the length and con- 
centration of the V3 peptides used ranging from 10 Hi to 
10 nu, depending on the E:T ratio used (Takahashi et 
al., 1988; Wagner et aI., 1992b). For this purpose, target 
cells were either incubated with the indicated V3 peptides 
(1 gM) or were labelled as targets by infection with the 
recombinant VVs (m.o.i. of 1) as described in Methods. 
The data summarized in Fig. 3 represent he mean 
percentage of specific lysis in three replicate cultures. 
In initial experiments (Fig. 3 a to c, i) splenocytes of 
BALB/c mice (H-2 d) were restimulated in vitro by 
syngenic targets infected with t e same recombinant VV 
that was used for the immunization. This procedure has 
been described by several groups and allows the 
stimulation of CTLs over a limited period without 
resulting in detectable ysis of effector cells within the test 
interval (Takahashi et al., 1988, 1989; Buseyne et al., 
1993). Restimulated effector cells were tested for cytolytic 
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Fig. 3. Induction of V3zA ~- or treatment with peptide V3c-16, and V3c-specific CTLs after immunization of BALB/c mice with 
recombinant VV as follows. (a) In vivo v-p55V3c-1, in vitro restimulation with v-p55V3c-1 (i) or V3c-16 (ii). (b) In vivo v-p55V3c-2, in
vitro restimulation with v-p55V3c-2 (i) or V3c-16 (ii). (c) In vivo v-p55V3c-3, in vitro restimulation with v-p55V3c-3 (i) or V3c-16 (ii). 
(d) In vivo with v-p55V3c-1 (i), v-p55V3c-2 (ii) orv-p55V3c-3 (iii) and in vitro with V3c-16 in all cases (see Methods). Peptides in (a), 
(b) and (c) are marked • nef-16, • V3c-16 and (3 V3~AI-16. Recombinant VV in (d) are marked [] v-p55V3c-1, /k v-p55V3c-2, © 
v-p55V3c-3, • v-gpl20, • v-p55gag and C) v-wx. 
activity against P815 cells pulsed with the peptides 
described in Methods. Only recombinant virus express- 
ing v-p55gag/V3-1, -2 or -3 (Fig. 3a to c, i), not a control 
virus expressing the HIV-1 gag gene alone (v-p55gag; not 
shown), could restimulate the effector cells in vitro to kill 
V3 peptide-pulsed P815 targets. Lysis of  target cells 
was observed irrelevant of  whether the homologous 
16-mer V3c peptide (V3c- 16; R IR IGPGRAFVT IGK I )  
or the heterologous V3LA~ peptide (V3LA~-16; 
R IQRGPGRAFVT IGK I )  was used for precoating tar- 
get cells. Pulsing the target cells with the peptide nef-16, 
LDLWIYHTCGYFPDWQNYTPG,  and incubation 
with the in vitro restimulated effector cells did not result 
in a specific lysis exceeding the spontaneous release, 
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which was below 7% for all peptides tested (1 ~tM). 
Splenocytes that were not restimulated in vitro did not 
recognize target cells following incubation with peptide 
V3c-16, with peptide V3LA~-16, or with control peptide 
nef-16 (not shown). These r sults demonstrated that the 
sequence variations between both tested V3 peptides did 
not affect recognition by the splenocytes. Altered residues 
flanking the translocated V3c loop as a result of the 
varying positions of the V3c sequence within p55 g~g had 
only a limited influence on the in vivo induction of CTLs. 
Insertion of the V3 domain into the p24-CA moiety of 
p55 g~g (v-p55gag/V3c-2), however, resulted in a slightly 
but reproducibly reduced specific lysis (Fig. 3 b). 
Similar results were obtained for each of the tested 
p55g~o/V3c chimeric antigens, when peptide V3c-16, not 
the control peptide nef-16 (not shown), was used for the 
in vitro restimulation. These data confirmed the cross- 
reactive properties of the V3c-primed CTLs with the LAI 
strain V3LAI-16 peptide (Fig. 3a to c, ii). In addition, we 
confirmed that altered flanking of the V3 domain had 
only a limited influence on the induction of V3-specific 
CTLs. Target cells pulsed with the peptide nef-16 as 
described above were not recognized. For BALB/c 
mice immunized with v-p55g~g/V3c-2, however, in vitro 
restimulation with V3c-16 reproducibly resulted, as with 
restimulation with the chimeric VV, in slightly decreased 
levels of lysis of the target cells. Control experiments 
using v-gpl20La ~for the in vivo stimulation of BALB/c 
mice gave identical results (Wagner et al., 1992b). 
In order to compare processing and presentation of 
the V3 antigenic peptide from the described p55g~g/V3 
chimeric proteins to that of the original gp 120LA~ external 
glycoprotein, splenocytes of BALB/c mice, immunized 
with the appropriate chimeric VVs, were stimulated in 
vitro by P815 cells pulsed with peptide V3c-16 or nef-16 
(Fig. 3d). Target cells were infected with the chimeric 
p55g~g/V3 VVs, with v-gp 120~A I and, for the control, with 
v-p55 g~g and wild-type VV (v-wa-). Placing the V3 epitope 
in different positions in the chimeric proteins in this 
study did not lead to significant differences in the 
efficiency of recognition of the V3 epitope by specific 
CTLs if compared to authentic gpl20LA I. Target cells 
infected by v-55 g~g or by v-wT were not killed (Fig. 3 d). 
Splenocytes that were restimulated by control peptide 
nef-16 did not recognize the pretreated target cells. In 
vitro restimulation ofsplenocytes with v-w3: and infection 
of the targets by the indicated recombinant VVs resulted, 
due to the induction of VV-specific CTLs, in specific lysis 
ranging from 60 % to 20 % depending on the E:T ratio 
used in the assay (not shown). 
Treatment of the CTL effector cells with anti-Lyt2 
MAb plus rabbit complement, but not with anti-L3T4 
antibody plus complement or with complement alone, 
led to a loss of killing activity in all cases tested, 
confirming previous data (Takahashi et al., 1988). This 
demonstrates that the effector cells recognizing and 
killing p55V3-1, -2 or -3 and gpl20-expressing, as well as 
V3 peptide-pulsed target cells, are conventional Lyt2 + 
L3T4 (CD8 + CD4-) CTLs (data not shown). 
In conclusion, our data suggest that the location of the 
V3 domain within the p55 gag carrier protein does not 
significantly influence the efficiency of recognition of the 
processed antigenic V3 peptide (Fig. 3 a to d). The results 
also demonstrate hat a selected omain, V3, known to 
include a CTL epitope can replace different regions 
within an antigenic carrier protein (p55 g~g) without 
significant loss of biological activity. 
Discussion 
Previous data indicated that the number of original 
residues flanking anoptimal CTL epitope seems to play 
a crucial role in the presentation of an antigenic peptide. 
Del Valet al. (1991) demonstrated that peptide sequences 
which are tightly flanking an optimal nonameric anti- 
genic recognition sequence of the murine cyto- 
megalovirus immediate arly protein pp89 are directly 
involved in antigen presentation. Lower amounts of the 
naturally presented antigenic peptide due to processing 
from an unfavourable site were shown to be r sponsible 
for improper antigen presentation. Our data demon- 
strated that this restriction can be completely overcome 
by allowing original flanking of the optimal V3 CTL 
epitope (Takahashi et al., 1988) by 10 amino acids. We 
could not find a difference between the processing of the 
V3 antigenic peptide from the p55 carrier protein, known 
to be translated on free ribosomes, and processing of the 
original gpl20 envelope protein, synthesized at and 
transported cotranslationally into the endoplasmic 
reticulum, thus confirming the cytoplasm as the site of 
glycoprotein fragmentation (Townsend et al., 1986). 
This considerably extended initial studies of Hahn et al. 
(1991), reporting that the recognition of an immuno- 
dominant influenza virus haemagglutinin site by CTLs is 
independent of the position of the site in the haemag- 
glutinin translation product. 
Minor differences in the in vivo induction of V3- 
specific CTL by v-p55g~g/V3c-2 in comparison to v- 
p55g~g/V3c-1 and v-p55g~g/V3c-3 might be due to an 
increased overall degradation rate of the latter two, 
previously suggested to improve antigen presentation 
slightly (Townsend et al., 1988). Putative conformational 
effects on local cleavage fficiency are difficult o prove or 
refute, but might also be involved in correct processing 
and antigen presentation. Assuming that the varying 
accessibility of the V3 domain within different chimeras 
for V3-specific antibodies reflects differences in the 
protein conformation, including the V3 loop (Fig. 2b to 
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d), it might be possible that altered flanking sequences 
influence processing and presentation of a translocated 
domain from chimeric proteins. These findings and 
considerations have important implications for the 
understanding of principles that govern antigen pres- 
entation and open new perspectives for a rational vaccine 
design. 
The development of severe immune dysfunctions 
following HIV infection is supposed to be induced, or at 
least supported, by the HIV-1 external glycoproteins. 
Vaccines restricted to immunologically defined epitopes 
might therefore avoid adverse side-effects. This paper 
showed that chimeric antigens, expressed via recom- 
binant VVs, are capable of inducing CTLs directed 
towards a translocated epitope. The insertion of more 
than one epitope into p55 gag by combining different 
chimeric genes might prove especially useful for those 
antigenic sites which can be presented by a number of 
different HLA haplotypes as shown e.g. for epitopes 
within the reverse transcriptase and the Nef regulatory 
protein (Walker et al., 1987, 1989; K6nig et al., 1990). 
Another important requirement for a rationally 
designed vaccine should be the induction of a humoral 
immune response allowing the neutralization of free 
virus in addition to the CTL-mediated elimination of 
infected cells. The efficacy of the V3 domain, proved in a 
series of experiments o be the principal HIV-1 neutral- 
izing determinant (Palker et al., 1988; Goudsmit et al., 
1988) has been discussed extensively by Berman et al. 
(1990), Emini et al. (1990), Girard et al. (1991) and 
Devash et al. (1990). We found this domain was suitable 
for analysis of the stimulation of both arms of the 
immune response. Using the p55g~g/v3 chimeric VVs as 
a live vaccine in rabbits, however, only low titres of V3- 
specific antibodies could be induced. With respect to the 
generation of a p55-specific humoral immune response, 
this was expected from previous tudies underlining the 
low immunogenicity of recombinant VVs expressing 
cytoplasmic proteins (v-p55) in comparison to purified 
antigen (Wagner et al., 1992a). Efficient stimulation of B 
lymphocytes might require larger amounts of free antigen 
than that released from cells infected by recombinant 
VVs. Induction of high titre neutralizing activity, as 
proved for branched synthetic V3 peptides (Shirai et al., 
1992), could present a useful approach in boosting V3- 
specific antibodies after primary immunization with 
chimeric VVs described above. 
Owing to the intrinsic adjuvant properties and high 
immunogenicity of particulate structures, alternative 
carrier systems have been developed for the presentation 
of heterologous epitopes recently, mainly based on the 
hepatitis B virus surface antigen, its core antigen or on 
yeast TyA particles (Kingsman et al., 1989; Beesley et al., 
1990; Schlienger et al., 1992). Extensive studies of the 
p55 g"g particle-forming capacity (Wagner et al., 1992a) 
and of the identification of domains necessary for correct 
assembly of the Gag precursor into immature virus-like 
particles (von Poblotzki et al., 1993) allowed us to 
establish a novel antigen presentation system. This 
system is based on recombinant p55 g"g virus-like particles 
which were previously shown to be highly immunogenic 
in rabbits (Wagner et al., 1992a). Placing immuno- 
logically defined regions uch as the V3 loop sequence in
different positions of the p55 gag precursor leads in some 
cases to the generation of chimeric p55gag/V3 virus-like 
particles (R. Wagner et al., unpublished). Further analy- 
sis of such virus-like particles will tell us more about the 
immunogenic potential of chimeric proteins and about 
the possibility of constructing a safe and effective 
candidate vaccine. 
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